Clinical Trial Update: A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of Tarceva (erlotinib) in patients with relapsed or refractory metastatic non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: NSCLC | Phase 2 | Status: TERMINATED